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The Effect of Umbilical Cord Blood Derived Mesenchymal Stem 
Cells in Monocrotaline-induced Pulmonary Artery Hypertension 
Rats
Pulmonary arterial hypertension (PAH) causes right ventricular failure due to a gradual 
increase in pulmonary vascular resistance. The purposes of this study were to confirm the 
engraftment of human umbilical cord blood-mesenchymal stem cells (hUCB-MSCs) placed 
in the correct place in the lung and research on changes of hemodynamics, pulmonary 
pathology, immunomodulation and several gene expressions in monocrotaline (MCT)-
induced PAH rat models after hUCB-MSCs transfusion. The rats were grouped as follows: 
the control (C) group; the M group (MCT 60 mg/kg); the U group (hUCB-MSCs 
transfusion). They received transfusions via the external jugular vein a week after MCT 
injection. The mean right ventricular pressure (RVP) was significantly reduced in the U 
group after the 2 week. The indicators of RV hypertrophy were significantly reduced in the 
U group at week 4. Reduced medial wall thickness in the pulmonary arteriole was noted in 
the U group at week 4. Reduced number of intra-acinar muscular pulmonary arteries was 
observed in the U group after 2 week. Protein expressions such as endothelin (ET)-1, 
endothelin receptor A (ERA), endothelial nitric oxide synthase (eNOS) and matrix 
metalloproteinase (MMP)-2 significantly decreased at week 4. The decreased levels of ERA, 
eNOS and MMP-2 immunoreactivity were noted by immnohistochemical staining. After 
hUCB-MSCs were administered, there were the improvement of RVH and mean RVP. 
Reductions in several protein expressions and immunomodulation were also detected. 
It is suggested that hUCB-MSCs may be a promising therapeutic option for PAH.
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INTRODUCTION
Pulmonary artery hypertension (PAH) leads to right ventricular 
failure and premature death (1). Although the pathophygiologi-
cal mechanisms of PAH are not known exactly, the key element 
in the pathogenesis of PAH is known as intima and media pro-
liferation and its consequent pulmonary vascular obstruction 
(2). PAH has been characterized as a disease of endothelial dys-
function with an imbalance between vasoconstrictors and va-
sodilators (3). With the identification of nitric oxide (NO) as an 
endothelium derived relaxing factor several studies have shown 
that PAH patients may have a reduced expression of eNOS in 
the vascular endothelium of the pulmonary arteries (4), although 
this has been contested by others (5). 
 There are several PAH animal models including chronic hy-
poxia (6), monocrotaline (MCT) injury (7) and hypoxia-Sugen 
5416 (8). From among these models, the most commonly used 
models of PAH are the chronic hypoxia model and the MCT in-
jury model (9). MCT is a pyrrolizidine alkaloid that causes a PAH 
in rats. Although the toxicological mechanisms of MCT are un-
clear, MCT pneumotoxicity is most widely used as a model of 
human pulmonary hypertension (7). It is difficult to make an 
early diagnosis and have a full recovery from PAH. There are 
difficulties in recovering pulmonary artery blood pressure us-
ing conventional drugs such as vasodilator, prostacyclin and 
anti-coagulants.
 Human umbilical cord blood-mesenchymal stem cell (hUCB-
MSC)s have recently been studied to evaluate their potential as 
a source of cell therapy (10). hUCB-MSCs could be a breakthrou-
gh to other incurable diseases because hUCB-MSCs can substi-
tute impaired vascular cells by paracrine-mediated effects and 
direct trans-differentiations in stem cells (11). However, it is rare 
to study hUCB-MSCs in PAH.
 The purposes of this study were to confirm the engraftment 
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of hUCB-MSCs in the lung and investigate changes of pulmonary 
pathology, hemodynamics, immunomodulation and several 
gene expressions in MCT-induced PAH rat models after hUCB-
MSCs injection.
MATERIALS AND METHODS
Animals
We used six-week-old male Sprague-Dawley rats for this research. 
All rats were kept in climate-controlled conditions with a 12 hr 
light/12 hr dark cycle, and were given full access to food and 
water. Pulmonary hypertension was induced by subcutaneous 
(sc) injection of 60 mg/kg MCT (Sigma Chemicals, St. Louis, 
MO, USA) dissolved in 0.5 N HCl solution. The rats were group-
ed as follows: control (C) group (n = 16), sc injection of saline, 
M group (n = 24), sc injection of MCT; hUCB-MSCs transfusion 
(U group) (n = 24). hUCB-MSCs (3 × 106 cells/rat) were adm-
nistered throught the external jugular vein 1 week after MCT 
injection. The animals were sacrificed at weeks 1, 2, and 3 after 
hUCB-MSCs transfusion. Tissues were extracted and were fro-
zen right away at -70°C. 
Estimation of mean RVP 
The animals were put in the supine position and instrumented 
with an arterial pressure line (Physiological Pressure Transduc-
er, MLT1199; AD Instruments, Oxfordshire, UK). Hemodynamic 
parameters were recorded at baseline and at weeks 2, 3, and 4. 
The catheter was put into the external jugular vein to estimate 
mean right ventricular pressure (RVP).
Organ weights
The rats were weighed and observed for general appearance 
throughout the research period. The animals were sacrificed at 
the scheduled time. The right ventricle (RV), left ventricle (LV) 
+septum (S), lung and kidney were weighed. We calculated or-
gan/body weight × 1,000. The RV to LV+S ratio (RV/[LV+S]) was 
used as an index of right ventricular hypertrophy (RVH). This 
method is based on our previous reports (12, 13). 
Two-photon microscopy
Two-photon microscopy (TPM) obtained 3-D images by ac-
quiring x-y plane images sequentially, while moving its focal 
plane stepwise in the z axis. In this experiment, two-photon ex-
citation wavelength we used was 750 nm for excitation of auto-
fluorescence and 1,050 nm for excitation of PKH26. Laser pow-
er at lung tissue sample was 72 mW and 36 mW in the case of 
750 nm and 1,050 nm, respectively. The excitation focus scann-
ed in the x-y plane of the sample by the scanners, and in the z 
axis by an objective translator P-725.4CL (Physik Instrumente, 
Karlsruhe, Germany). Emission light from the sample was col-
lected back by the objective lens and was reflected on dichroic 
mirror (DM, 680DCLP, Chroma, Rockingham, VT, USA) toward 
photomultiplier tubes (PMTs, R5929, Hamamatsu, Japans). We 
calculated PKH26 density % area using Image J software.
Histopathological examination 
3 μm sections of paraffin thickness were stained with hematox-
ylin & eosin and Victoria blue straining. We used visual imaging 
system to disitize the image digitized by using image-Pro plus 
6.0 program. Measurements were randomly made on 30 mus-
cular arteries per lung section in 25-100 μm sized vessels in each 
photographic field. We measured the medial wall thickness be-
tween the internal and external elastic lamina of two sides of 
muscular arteries (M1 and M2). The percentage of wall thick-
ness was calculated as follows: % wall thickness = (M1+M2)/di-
ameter of the vessel × 100. For pathological assessment of neo-
muscularization, the numbers of the muscularized vessels with 
diameter < 50 μm were measured in a × 200 magnification 
field below the terminal bronchiole. Twenty fields were exam-
ined in each rat for this analysis (13).
Western blot analysis
The tissues were homogenized in 10 mM Tris HCl buffer, pH 7.4 
containing 0.5 mM EDTA, pH 8.0, 0.25 M sucrose, 1 mM PMSF, 
1 mM Na4VO3 and a protease inhibitor cocktail (Roche-Boeh-
ringer-Mannheim, Mannheim, Germany). After centrifugation, 
the supernatant was subjected to sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE). Samples equiva-
lent to 25 μg of protein content were loaded and size-separated 
in 8%-12% SDS-PAGE. The proteins on the acrylamide gel were 
transferred to a polyvinylidene difluoride membrane (Millipore, 
Bedford, MA, USA) at 400 mA in a transfer buffer containing 25 
mM Tris and 192 mM glycine, pH 8.4. The nitrocellulose mem-
branes was blocked in TBS with 5% non-fat dry milk at room 
temperature for 1 hr in 0.1% Tween 20 and incubated with the 
optimal primary antibodies, including ET-1 (SantaCruz biotech-
nology, Santacruz, CA, USA), ERA (SantaCruz biotechnology, 
Santacruz, CA, USA), eNOS (SantaCruz biotechnology, Santa-
cruz, CA, USA), and MMP-2 (Cell Signaling Technology Inc., 
Danvers, MA, USA) and GAPDH (SantaCruz biotechnology, 
Inc., Santacruz, CA, USA), at 4°C overnight. The membrane was 
incubated with horseradish peroxidase-conjugated secondary 
antibody (Cell Signaling Technology Inc., Danvers, MA, USA) 
for 1 hr at room temperature. After washing, the membrane was 
visualized by a chemiluminescent reaction using an ECL-detec-
tion kit system from GE Healthcare (Amersham Bioscience, Pis-
cataway, NJ, USA). 
Cell preparation
hUCB-MSCs were obtained from Medipost Inc. (Biomedical 
research institute Co., Ltd, Seoul, Korea) and isolated human 
MSCs were expanded in culture according to the method of the 
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previous report (14). Briefly, mononuclear cells (MNCs) isolat-
ed from hUCB were washed, suspended in alpha-minimum 
essential medium (α-MEM, Gibco-Invitrogen, Carlsbad, CA, 
USA) supplemented with 10% fetal bovine serum (FBS, Gibco-
Invitrogen, Grand island, NY, USA). hUCB-MSCs were attached 
to plastic culture dishes during the culture period and exhibited 
spindle-shaped fibroblast-like morphology at passage 5. 
Immunohistochemistry
We incubated the lung tissues overnight in 10% buffered for-
malin. Four-micron sections were cut from paraffin embedded 
tissue blocks and deparaffinized in zylene and rehydrated in 
graded alcohols (100%-70%). Heat antigen retrieval was obtain-
ed by boiling of tissue sections in antigen retrieval solution pH 
6.0 or pH 9.0 (Dako, Carpinteria, CA, USA) for 10 min in micro-
wave prior to incubation at 4°C overnight with primary antibo-
dies against ET-1 (SantaCruz biotechnology, Santacruz, CA, 
USA), ERA (SantaCruz biotechnology, Santacruz, CA, USA), eNOS 
(SantaCruz biotechnology, Santacruz, CA, USA) and MMP-2 
(Abcam, Campridge, UK). After incubation with the optimal bi-
otinylated secondary antibodies for 30 min at 4°C and afterwards 
with a streptavidin (Dako, Kyoto, Japan), color development 
was done using 3-amino-9-ethylcarbazole or DAB as a chro-
mogen. 
Cytokine array and gene expression in lung tissues
Lung samples were collected at termination (3 week after hUCB-
MSCs injection) and quickly frozen in liquid nitrogen. A rat cy-
tokine array (ARY008, R&D Systems, Minneapolis, MN, USA) 
was performed on lung homogenates according to manufac-
turer’s instructions to screen whether hUCB-MSCs treatment 
suppress local secretion of specific inflammatory cytokines by 
Fig. 1. Human UCB-MSCs preparation. Characterization of hUCB-MSCs at passage 5. hUCB-MSCs by phase-contrast microscopy (A). Cells grow uniformly and have a spindle-
shape (left). PKH26-labeled MSCs are stained in red (middle, × 200). Immunophenotype from UCB-hMSCs (B). These cells are positive for antigens CD73, CD90 and CD105 
but generally not for antigens HLA-DR, CD34 and CD45. The gray lines indicate the isotype matched mouse IgG antibody control labeling. 
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the host lung cells. Samples were pooled per treatment group 
and equal amounts of protein were loaded on the blots. From 
all pooled samples blots were performed in duplicate and aver-
ages of these two pixel densities were used to calculate the aver-
age density with Image J software. Background staining and spot 
size were analyzed as recommended by the manufacturer. Brief-
ly, pictures were converted to 8-bit inverted jpeg files and spots 
were encircled. Per blot, equal spot sizes were analyzed.
Statistical analysis 
Results are showed as the means ± standard deviation. We used 
an unpaired two-tailed t-test and Mann-Whitney test. We con-
sidered a P value < 0.05 statistically significant. SPSS 14.0 for 
Windows (SPSS, Chicago, IL, USA) was used for all statistical 
analyses. 
Ethics statement
All animal experimental procedures were approved by the in-
stitutional animal care and use committee (IACUC) of the Sch-
ool of Medicine of Ewha Womans University in 2013 (approval 
number. 13-0234).
RESULTS
Characterization and immunophenotype from hUCB-MSCs
We found that hUCB-MSCs grew uniformly. They appeared to 
be spindle-shaped (left). PKH26-labeled hUCB-MSCs were stain-
ed in red (middle). We did not observe any trypan blue positive 
cells (red: PKH26, blue: trypan blue) (Fig. 1A). The cells were 
positive for the cell surface markers CD73, CD90, and CD105, 
but negative for the hematopoietic cell-specific surface markers 
CD34, CD45, as well as for the MHC class II marker HLA-DR. 
The gray lines indicate the isotype matched the mouse Ig G an-
tibody control labeling (Fig. 1B). We were able to identify hUCB-
MSCs at passage 5 with a CD73+, CD90+, CD105+, CD34-, CD45-, 
and HLA-DR. hUCB-MSCs did not express hematopoietic mark-
ers; CD45+, CD34+, CD105-, CD73-, CD90-. Characterization of 
hUCB-MSCs by flow cytometry was performed in a cultured cells. 
Engraftment of hUCB-MSCs in the lung tissues
We confirmed that the hUCB-MSCs were engrafted in the lung 
tissues using two-photon microscopy. In the U group, white cir-
cular forms were observed at 1,050 nm wave length which could 
be hUCB-MSCs. These white circular forms in the U group were 
more lighter in color compared than those in both C and M group 
(Fig. 2). PKH-26 detection % area was greater in the U group than 
the C or M group (C vs. M vs. U; 1.00 vs. 0.87 vs. 1.43)
Changes in RVP and RV/LV+S after hUCB-MSCs injection 
in PAH rats
The mean RVP was significantly increased in the M group com-
pared with the C group at weeks 2, 3, and 4. RVP was significant-
ly decreased in the U group compared with the M group at weeks 
2, 3, and 4 (Table 1). RV/LV+S was significantly increased in the 
M group at weeks 2, 3, and 4. RV/LV+S was significantly decre-
as ed in the U group at 4 week (Table 2). 
Organ weight
The body weight was significantly decreased in the M group com-
pared with the C group at weeks 3 and 4. The RV/body weight 
was significantly increased in the M group compared with the 
C group at weeks 2, 3, and 4 and significantly decreased in the 
C group M group U group
Fig. 2. Engraftment of hUCB-MSCs in lung tissues. The hUCB-MSCs tagged by PKh-26 are observed at 1,050 nm wave length in the lung tissues. Light circular forms are con-
sidered to UCB-MSCs engrafted. C, control group; M, monocrotaline group; U, hUCB-MSCs group (Field of view: 300 µm).
Table 1. Changes of right ventricular pressure after hUCB-MSCs injection in PAH rats 
(mmHg)
Week C M U
2 11.0 ± 0.0 36.5 ± 3.1* 23.6 ± 7.6†
3 11.5 ± 0.7 37.2 ± 6.3* 21.3 ± 4.9†
4 10.5 ± 2.1 52.0 ± 19.7* 16.5 ± 3.6†
*P < 0.05 compared with the C group; †P < 0.05 compared with the M group. C, con-
trol group; M, monocrotaline group; U, hUCB-MSCs group. Values are means ± SD.
Table 2. Changes of RV/LV+S ratio after hUCB-MSCs injection in PAH rats
Week C M U
2 1.00 ± 0.05 1.47 ± 0.18* 1.43 ± 0.14
3 1.00 ± 0.46 2.89 ± 0.43* 2.18 ± 0.45
4 1.00 ± 0.07 2.88 ± 0.58* 1.85 ± 0.28†
*P < 0.05 compared with the C group; †P < 0.05 compared with the M group. C, con-
trol group; M, monocrotaline group; U, hUCB-MSCs group. Values are means ± SD.
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U group compared to the M group at week 4. The lung/body wei-
ght was significantly increased in the M group compared with 
the C group at weeks 2, 3, and 4 (Table 3). 
Pathological changes in the lung tissues
Fully muscularized arteries were only seen in pulmonary arte-
rioles (> 10 μM, < 100 μM) in the M group and the U group. Pul-
monary arterioles in the U group showed decreased tendency 
of medial wall thickening by Victoria blue straining (Fig. 3). 
 The M group showed a significant increase in medial wall thick-
ness compared to the C group at weeks 2, 3, and 4. The U group 
showed significant reductions in medial thickness at the 4 week 
compared with the M group (Table 4A, Fig. 3). 
 The number of muscular intra-acinar arteries in the M group 
was significantly increased compared to the C group at weeks 2, 
3, and 4 and significantly decreased in the U group at weeks 2, 3, 
and 4 compared with the M group (Table 4B, Fig. 3).
Immunohistochemistry analysis in the lung tissues
Immunohistochemical expressions revealed that the positive 
cells of ET-1, ERA, eNOS, and MMP-2 were significantly higher 
in the M group than the C group, however, ERA, eNOS, and MMP-
2 were lower in the U group than the M group (Fig. 4A). This re-
sult indicated that hUCB-MSCs could attenuate the vascular 
remo deling. The increased levels of ET-1, ERA, eNOS, and MMP-
2 immunoreactivity observed in the M group were statistically 
significant. Three weeks after hUCB-MSCs transfusion, levels of 
ERA, eNOS, and MMP-2 immunoreactivity were significantly 
decreas ed in the U group compared with the M group (Fig. 4B). 
Western blot analysis in the lung tissues
The protein expressions of ET-1, ERA, eNOS, and MMP-2 were 
significantly increased in the M group compared with the C 
C group M group U group
Fig. 3. Photographs of peripheral pulmonary arteries in the three groups after Victoria blue straining ( × 400). The medial layer of the pulmonary arterioles thickened progres-
sively after the monocrotaline injection. The medial wall thicknesses was significantly reduced in the U group at week 4. C, control; M, monocrotaline; U, hUCB-MSCs.
Table 3. Changes of body and organ weights after hUCB-MSCs injection in PAH rats
Week Group Body Wt (g) RV/Body Wt LV/Body Wt Lung/Body Wt Kidney/Body Wt Liver/Body Wt
2 C
M
U
338.63 ± 13.88
278.50 ± 27.69
308.56 ± 25.85
0.62 ± 0.02
1.01 ± 0.10*
1.14 ± 0.21
2.20 ± 0.05
2.34 ± 0.11
2.43 ± 0.17
4.18 ± 0.34
7.10 ± 1.15*
8.50 ± 1.37
4.35 ± 0.16
4.33 ± 0.50
4.52 ± 0.36
4.21 ± 0.18
4.77 ± 0.29*
4.31 ± 0.41
3 C
M
U
293.75 ± 19.45
266.67 ± 54.35*
251.00 ± 37.94
0.40 ± 0.18
1.62 ± .0.24*
1.72 ± 0.33
1.99 ± 0.00
2.16 ± 0.08
2.32 ± 0.23
3.24 ± 0.14
10.05 ± 3.67*
10.93 ± 2.10
4.01 ± 0.14
4.15 ± 0.32
4.37 ± 0.40
4.14 ± 0.31
4.07 ± 0.31
4.22 ± 0.40
4 C
M
U
404.00 ± 36.77
248.89 ± 40.96*
279.29 ± 26.58
0.61 ± 0.04
2.67 ± 0.04*
1.81 ± 0.15†
0.61 ± 0.04
2.67 ± 0.04
1.81 ± 0.15
3.68 ± 0.05
9.28 ± 3.29*
8.92 ± 1.67
4.26 ± 0.30
4.38 ± 0.38
4.02 ± 0.21
3.77 ± 0.30
3.90 ± 0.49
3.69 ± 0.39
*P < 0.05 compared with the C group; †P < 0.05 compared with the M group. C, control; M, monocrotaline; U, hUCB-MSCs; Wt, weight; RV, right ventricle; LV, left ventricle. 
Values are means ± SD.
Table 4. Changes of medial wall thickness and the number of intra acinar-arteries 
after hUCB-MSCs injection in PAH rats
A. Medial wall thickness
Week C M U
1 25.9 ± 0.4 25.3 ± 2.2 28.4 ± 3.3
2 22.1 ± 2.9 38.5 ± 4.0* 34.2 ± 4.0
3 23.7 ± 1.0 38.8 ± 6.3* 33.2 ± 3.9
4 22.5 ± 0.4 32.3 ± 2.5* 37.3 ± 1.5†
B. The number of intra-acinar arteries
Week C M U
1 1.16 ± 0.18 1.62 ± 0.20 1.79 ± 0.02
2 0.71 ± 0.07 2.01 ± 0.11* 1.61 ± 0.20†
3 1.05 ± 0.04 2.23 ± 0.29* 1.27 ± 0.02†
4 1.15 ± 0.22 2.78 ± 0.40* 1.45 ± 0.34†
*P < 0.05 compared with the C group; †P < 0.05 compared with the M group. C, con-
trol group; M, monocrotaline group; U, hUCB-MSCs group. Values are means ± SD.
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Fig. 4. Localization of ET-1, ERA, eNOS and MMP2-immunoreactive cells in the lung tissues at week 4. Immunohistochemical expressions revealed that the positive cells of ET-
1, ERA, eNOS, and MMP-2 were significantly higher in the M group than the C group, however, they were lower in the U group than the M group (A). The increas ed levels of ET-
1, ERA, eNOS, and MMP-2 immunoreactivity observed in the M group were statistically significant. The levels of ERA, eNOS, and MMP-2 immunoreactivity were significantly 
decreased in the U group compared with the M group (B). *P < 0.05 compared with the C group. †P < 0.05 compared with the M group. C, control group; M, monocrotaline 
group; U, hUCB-MSCs group. Scale bars = 40 µm (A-C, G-I, M-O, S-U), 10 µm (D-F, J-L, P-R, V-X).
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group at weeks 2 and 4. The protein expressions of ET-1, ERA, 
eNOS, and MMP-2 were significantly decreased in the U group 
compared with the M group at week 4 (Fig. 5).
Cytokine profile is altered after hUCB-MSCs treatment  
in the lung tissues 
To screen whether hUCB-MSCs affected local production of in-
flammatory cytokines to many kinds of cells in the lung tissues 
in three groups, a cytokine array was performed on lung ho-
mogenates (Fig. 6A). Nine inflammatory cytokines such as cy-
tokine-induced neutrophil chemoattractant-1 (CINC-1); cyto-
kine-induced neutrophil che moattractant-2a/b (CINC-2a/b); 
chemokine (C-X-C motif) ligand 1 (CX3CL1); inter-cellular ad-
hesion molecule 1 (ICAM-1); lipopolysaccharide-induced CXC 
chemokine (LIX); leukocyte endothelial cell adhesion molecule 
1 (LECAM-1); chemokine (C-X-C motif) ligand 7 (CXCL7); tis-
sue inhibitor of metalloproteinase 1 (TIMP-1) and vascular en-
dothelial growth factor (VE -GF) were performed in three groups. 
CINC-1, ICAM-1, LIX, LE CAM-1, CXCL7, and VEGF were high-
er in the M group, whereas CINC-1, ICAM-1, LIX, LECAM-1, 
CXCL7, and VEGF were lower in the U group compared to the 
M group. CINC-2a/b, CX3CL1, and TIMP-1 were not different 
in three groups (Fig. 6B).
DISCUSSION
In this study, we demonstrated that hUCB-MSCs (3 × 106 cells/
rat) which were injected via the external jugular vein in the lung 
tissues of MCT-induced PAH rats. It remain ed for 3 weeks after 
injection. Adverse effects were not observed after hUCB-MSCs 
transfusion. hUCB-MSCs attenuated MCT-induced PAH. The 
mean RVP was significantly reduced in the U group after 2 week. 
The RV/LV+S ratio and RV/body weight were significantly de-
creased at week 4; Decreased number of intra- acinar muscular 
arteries was noted after 2 week and significant reductions in 
medial thickness of pulmonary arterioles were also observed at 
the 4 week; Protein expressions such as ET-1, ERA, eNOS, and 
MMP-2 significantly decreased at week 4; The decreased levels 
of ERA, eNOS, and MMP-2 immunoreactivity were observed by 
immnohistochemical staining at week 4.
 We confirmed by two photon microscopy that hUCB-MSCs 
were engrafted in the lung tissues. PKH-26 labled hUCB-MSCs 
were identified for 3 weeks after injection in the lung tissues. 
They were clustered in a circular form and weakly spread in the 
extracellular matrix of lung tissues in PAH rats. This means that 
hUCB-MSCs injected via the external jugular vein can be wide-
ly distributed in the lung tissues by pulmonary arterioles and 
remain for at least 3 weeks. Also, we noted that the injected cells 
were engrafted more in the damaged area of the lung. In this 
study, MCT may cause a rapid progression of PAH before hUCB-
MSCs produce effect including paracrine effect such as anti-in-
flammatory cytokine effect. As already known, most stem cells 
need transdifferentiation. It takes time to show therapeutic ef-
fect of hUCB-MSCs because MCT already caused histomorpho-
logic changes in the lungs and RV. 
 Vascular remodeling occurred in our PAH rats. Vascular re-
Fig. 6. Inflammatory cytokine expressions in the lung tissues. To screen whether hUCB-MSCs affected local production of inflammatory cytokines by lung cells in three groups, a 
cytokine array was performed on lung homogenates (A) CINC-1, ICAM-1, LIX, LECAM-1, CXCL7, and VEGF were higher in the M group, whereas CINC-1, ICAM-1, LIX, LECAM-1, 
CXCL7, and VEGF were lower in the U group compared to the M group. CINC-2a/b, CX3CL1, and TIMP-1 were not different in three groups (B). White bars, control (n = 6); gray 
bars, monocrotaline (n = 6); black bars, hUCB-MSCs (n = 7). CINC-1, cytokine-induced neutrophil chemoattractant-1; CINC-2a/b, cytokine-induced neutrophil chemoattractant-
2a/b; CX3CL1, chemokine (C-X-C motif) ligand 1; ICAM, inter-cellular adhesion molecule; LIX, lipopolysaccharide-induced CXC chemokine; LECAM-1, leukocyte endothelial cell 
adhesion molecule 1; CXCL7, chemokine (C-X-C motif) ligand 7; TIMP-1, tissue inhibitor of metalloproteinase 1; VEGF, vascular endothelial growth factor. *P < 0.05 compared 
with the C group, †P < 0.05 compared with the M group. C, control; M, monocrotaline; U, hUCB-MSCs.
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modeling is accompanied by a thickening of the arterieal wall 
after 2 week which is thought to increase resistance by physical 
encroachment of the lumen of small peripheral pulmonary ar-
teries and arterioles. Angiogenesis in pulmonary vessels also 
occurred in the MCT treated groups. The number of intraacinar 
arteries were increased in the M group after 2 week. The protein 
expressions of ET-1, ERA, eNOS, and MMP-2 were significantly 
increased in the M group after 2 week.
 Immunohistochemical staining revealed that the positive 
cells of ET-1, ERA, eNOS, and MMP-2 expression were signifi-
cantly higher in endothelium and smooth muscle layers in the 
M group. 
 We suggested the effects of hUCB-MSCs on ET-1, ERA, eNOS, 
and MMP-2. First, a key regulator of PAH, ET-1 was increased in 
the M group. Under the influence of hUCB-MSCs, the protein 
expression level of ET-1 was decreased in the U group. Second, 
ERA was increased in the M group. The protein expression level 
of ERA was significantly decreased in the U group. Presently, 
there are several types of ET receptor antagonists including bo-
sentan, ambresentan and sataxentan (15). But these non-pep-
tide chemical drugs have little effect on PAH in contrast with 
hUCB-MSCs. Third, NO, synthesized largely by eNOS in endo-
thelial cell (EC), is a vasodilator and a suppressor of smooth 
muscle cell (SMC) proliferation. ECs in PAH patients, produce 
decreased amounts of NO. In our study, the eNOS expression 
level was increased in the M group and UCB-MSCs had a sig-
nificantly decreased effect on eNOS. Although the molecular 
mechanisms of pulmonary vascular remodeling is unclear, cer-
tain extracellular matrix (ECM) components are likely to be in-
volved. PAH is characterized by an accumulation of ECM com-
ponent in the lung including MMP-2. It is known to be involved 
in the migration and proliferation in SMCs, and ECs. There have 
already been reports that MMP-2 expression is increased in 
PAH. Our data also shows similar results compared with our 
previous data (12). 
 hUCB-MSCs are regarded as an alternative source of bone 
marrow-derived MSCs because the collection of cord blood is 
less invasive than that of bone marrow. The clinical use of bone 
marrow MSCs has presented problems, including pain, morbi-
dity, and age-related diseases (16). Our present study revealed 
that the effect of hUCB-MSCs seems to be superior to bone mar-
row cells in the depression of gene expressions when we com-
pared with our previous studies (13). 
 The mechanisms underlying the possible in vivo immuno-
modulatory effects of hUCB-MSCs remain a critical and unre-
solved question (17). Cytokines and chemokines are known to 
play important roles in a number of biological processes, in-
cluding immunity, apoptosis, angiogenesis and cell differentia-
tion (18). Many of these processes are involved in pathogenesis 
and therapy (18). LIX, CXCL7 and CINC-1 are member of the 
CXC chemokine family which are potent neutrophil chemoat-
tractants. ICAM-1 and LECAM-1 have been reported to inhibit 
the interaction between T cells and block NK cell-mediated 
toxicity, suggesting a pathogenesis promoting role (19). Recent-
ly, the role of VEGF have also been suggested in PAH (20). VEGF 
may be an important mediator of lung growth and responsible 
for angiogenesis and vasculogenesis (20). In our study, we show-
ed the changes in chemokine, cytokine and growth factor levels 
after hUCB-MSCs transfusion in MCT induced PAH rats. Of 
these factors, immunomodulation and inflammation regulated 
by various types of cytokines are some of the key pathways which 
interact with each other in hUCB-MSCs and PAH. Our present 
study provides an understanding of the biology of hUCB-MSCs 
therapy and use of anti-cytokine and growth factor therapies.
 Recently, in a well-established PAH model, it has been dem-
onstrated that MSC injection can have a favorable effect on pul-
monary vasculature, pulmonary pressure and RV structure and 
function (21). MSC is regarded to have an effect on cardiovas-
cular disease, degenerative joint disease and acute lung injury. 
And the expected effectiveness of MSC is to increase anti-in-
flammatory cytokines, positive neurohormonal response and 
positive pulmonary vascular remodeling (22). MSC can be con-
sidered to be acquired from the umbilical cord at present (23). 
Adult stem cells are helpful in treating and repairing injured tis-
sues and it can be an alternative source of embryonic stem cells. 
The transplantation of cord blood has been part of clinical prac-
tice for more than 10 yr (24). Randomized and nonrandomized 
clinical trials have been tried with a variety of stem cells, includ-
ing bone marrow derived cells, endothelial precursor cells and 
MSC (25). However, it is still a controversial issue whether MSCs 
from human umbilical cord blood are capable of differentiation 
into pulmonary vascular epithelial cells in vivo (26, 27). Recent 
studies confirmed that MSCS, hematopoietic stem cells and 
other populations could successfully structurally engraft upon 
mature differentiated airway and alveolar epithelial (28, 29).
 Meanwhile, administration of hUCB-MSCs via the external 
jugular vein route used in this study did not cause an immune 
response and there was a high probability to arrive at the desig-
nated site in the lung. In 2009, there was a report that a direct 
administration of hUCB-MSCs to neonatal rats by the trachea 
decreased inflammation related factors in the lung more effec-
tively than intraperitoneal injection. Because they did not use 
the same dose of hUCB-MSCs, direct comparison between our 
study is difficult (30). In 2006, in Barber’s study, MSCs improved 
blood vessel endothelial cell functions in MCT induced PAH rat 
(31). In our present study, endothelial dysfunction was improved. 
 There are a lot of treatment options for PAH, but an effective 
therapy still does not exist. Therefore, there may be many possi-
bilities for applications of hUCB-MSCs on PAH. Advantages in-
clude decreased pulmonary arteriole thickening and several 
gene expressions compared with other chemical drugs. 
 The limitations of our study are as follows. First, the sample 
Lee H, et al. • The Effect of hUCB-MSCs in Pulmonary Hypertension 
584  http://jkms.org http://dx.doi.org/10.3346/jkms.2015.30.5.576
size is small and the follow-up duration is relatively short. Sec-
ond, we did not check the transdifferentiation of hUCB-MSC 
and just confirmed hUCB-MSCs engraftment. It is considered 
that further studies about transdifferentiation are needed. 
 Future studies with larger sample sizes and a longer follow-up 
duration will be required to determine the appropriate amount 
of hUCB-MSCs, frequency and time interval required for PAH 
treatment.
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